非酒精性脂肪性肝病所致晚期肝纤维化患者HDL结合载脂蛋白的差异
这项在大学医院开展的横断面研究纳入185例伴或不伴2型糖尿病的患者,采用靶向蛋白质组学检测HDL结合蛋白,发现晚期肝纤维化患者HDL-C更低、HDL颗粒数更少,5种HDL结合蛋白降低,pCAD指数更高。
要点
- 晚期肝纤维化患者HDL-C为34±8 mg/dL,低于无晚期纤维化者的38±9 mg/dL(P=0.024)。
- 晚期肝纤维化患者HDL颗粒数更低,ApoC-I、ApoC-IV、ApoM、LCAT、SAA4五种HDL结合蛋白降低。
- 晚期肝纤维化患者pCAD指数为97±5,高于无晚期纤维化者的86±25(P=0.04)。
核心结论
- 伴晚期肝纤维化的NAFLD患者HDL结合蛋白水平存在显著差异,基于pCAD指数转译为心血管风险增加。
- 脂蛋白组成与功能的不同可能解释肝病与心血管死亡率增加之间的联系。
研究设计与样本
- 在大学医院开展的横断面研究,纳入185例伴或不伴2型糖尿病的患者。
- 患者接受肝脏质子磁共振波谱测量肝内甘油三酯蓄积,NAFLD患者接受经皮肝活检。
- 进行脂蛋白亚组分检测的advanced lipid testing及HDL结合蛋白的靶向蛋白质组学检测。
主要发现
- 伴与不伴晚期纤维化患者临床特征相似,但晚期纤维化组HDL-C更低(34±8 vs 38±9 mg/dL,P=0.024)且2型糖尿病患病率更高。
- 晚期纤维化患者HDL颗粒数更低。
- 靶向定量28种HDL结合蛋白,发现5种在晚期纤维化患者中降低:ApoC-I(P<0.001)、ApoC-IV(P=0.012)、ApoM(P=0.008)、LCAT(P=0.014)、SAA4(P=0.016)。
- 上述蛋白在有无NAFLD或脂肪性肝炎的患者之间未见差异。
- 与冠状动脉疾病和心血管死亡相关的pCAD指数在晚期纤维化患者中显著更高(97±5 vs 86±25,P=0.04)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The mechanisms leading to increased cardiovascular disease in patients with nonalcoholic fatty liver disease (NAFLD) and advanced liver fibrosis remain incompletely understood. OBJECTIVE: This study assessed HDL-bound proteins in patients with NAFLD with or without advanced fibrosis. METHODS: This cross-sectional study at a university hospital included 185 patients with or without type 2 diabetes (T2D). Patients underwent liver proton magnetic resonance spectroscopy to measure intrahepatic triglyceride accumulation and those with NAFLD underwent a percutaneous liver biopsy. Advanced lipid testing with lipoprotein subfraction measurements and targeted proteomics of HDL-bound proteins was performed. RESULTS: Patients with and without advanced fibrosis had similar clinical characteristics, except for lower HDL-C (34 ± 8 vs 38 ± 9 mg/dL, P = 0.024) and higher prevalence of T2D in advanced fibrosis. Patients with advanced fibrosis had lower HDL particle number. A panel of 28 HDL-bound proteins were targeted and quantified by multiple reaction monitoring liquid chromatography-tandem mass spectrometry. Five proteins were found to be decreased in patients with advanced fibrosis (ApoC-I [P < 0.001], ApoC-IV [P = 0.012], ApoM [P = 0.008], LCAT [P = 0.014], and SAA4 [P = 0.016]). No differences were observed in these proteins in patients with vs without NAFLD or steatohepatitis. The pCAD index, associated with coronary artery disease and cardiovascular mortality, was significantly higher in patients with advanced fibrosis (97 ± 5 vs 86 ± 25, P = 0.04). CONCLUSION: Patients with NAFLD with advanced fibrosis showed significant differences in HDL-bound protein levels; this translated into increased cardiovascular risk based on pCAD index. Different lipoprotein composition and function may explain the link between liver disease and increased cardiovascular mortality in these patients.
引用
- Bril F, Pearce RW, Collier TS, et al. Differences in HDL-Bound Apolipoproteins in Patients With Advanced Liver Fibrosis Due to Nonalcoholic Fatty Liver Disease. J Clin Endocrinol Metab. 2022. PMID: 36173828. doi:10.1210/clinem/dgac565
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。